Cost-Effectiveness of Zoledronic Acid Versus Oral Alendronate for Postmenopausal Osteoporotic Women in China

You, Ruxu; Wu, David Bin-Chia; Liu, Jinyu; Qin, Xinyu; Luo, Nan; Mori, Takahiro

doi:10.3389/fphar.2020.00456

Cited by 14 publications

(27 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Women with creatinine clearances of less than 30–35 mL/min should not receive ZA or oral bisphosphonates. Cost-effective analyses show that denosumab is more cost-effective than oral bisphosphonates for treating osteoporosis [ 104 ], and ZA is more cost-effective than oral alendronate in Chinese women with osteoporosis [ 105 ].…”

Section: Oral and Intravenous Bisphosphonates And Rank Ligand Inhimentioning

confidence: 99%

Osteoporosis: A Long-Term and Late-Effect of Breast Cancer Treatments

Shapiro

2020

Cancers

View full text Add to dashboard Cite

Osteoporosis is both a long-term effect (occurs during treatment and extends after treatment) and a late-effect (occurs after treatment ends) of breast cancer treatments. The worldwide prevalence of osteoporosis is estimated to be some 200 million patients. About one in three postmenopausal women will experience an osteoporotic (or fragility) fracture of the hip, spine, or wrist. breast cancer treatments, including gonadotropin-releasing hormone (GnRH) agonists, chemotherapy-induced ovarian failure (CIOF), and aromatase inhibitors (AIs), cause bone loss and increase the risks of osteoporosis. Also, breast cancer is a disease of aging, and most of the “one in eight” lifetime risks of breast cancer are in women in their sixth, seventh, and eighth decades. The majority of women diagnosed with breast cancers today will be long-term survivors and experience personal cures. It is the coalescence of osteoporosis with breast cancer, two common and age-related conditions that make osteoporosis relevant in women with breast cancer throughout the continuum from diagnosis, treatment, and survivorship. It is critical to remember that women (and men) will lose bone after age thirty years. However, only certain women will lose bone of sufficient magnitude to merit treatment with anti-osteoporosis drugs. The narrative review is intended for medical, surgical, radiation oncologists, and other mid-level providers, and provides an overview of bone loss and the prevention and treatment of osteoporosis.

show abstract

Section: Oral and Intravenous Bisphosphonates And Rank Ligand Inhimentioning

confidence: 99%

Osteoporosis: A Long-Term and Late-Effect of Breast Cancer Treatments

Shapiro

2020

Cancers

View full text Add to dashboard Cite

show abstract

“…In our previous study ( You et al, 2020 ), in which we examined the cost-effectiveness of once-yearly injection of zoledronic acid compared with oral alendronate once a week for postmenopausal osteoporotic women without prior history of fracture in China, we concluded that zoledronic acid was cost-effective at all starting ages and even cost-saving in scenario analysis mainly based on zoledronic acid’s higher persistence leading to higher efficacy. In this study, we came to a similar conclusion that medication persistence plays a key role in shaping perceptions of fracture risk and osteoporosis drug effectiveness.…”

Section: Discussionmentioning

confidence: 99%

“…The development of this model adhered to the recommendations for the conduct of economic evaluations in osteoporosis ( Hiligsmann et al, 2019 ). We used an updated version of the previously validated individual-level state-transition model ( You et al, 2020 ) to estimate the impact of the compliance and persistence on the cost-effectiveness of alendronate treatment for Chinese postmenopausal osteoporotic women aged 65 and older. The model estimated the outcomes including the number of fracture quality-adjusted life-years (QALYs); direct societal costs in 2018 US dollars (USD); and incremental cost-effectiveness ratios (ICERs) per QALY gained.…”

Section: Methodsmentioning

confidence: 99%

“…Table 1 shows the key parameters used in the health economics model. A more detailed description of the model can be found in our previously published work ( You et al, 2020 ).…”

Section: Methodsmentioning

confidence: 99%

“…In our recent study ( You et al, 2020 ), we demonstrated the cost-effectiveness of yearly intravenous zoledronic acid, which has a higher persistence and compliance rate. Further economic evaluation of alendronate is an evidence gap that could inform prescribers about the potential loss of benefits resulting from poor compliance and persistence.…”

Section: Introductionmentioning

confidence: 91%

See 2 more Smart Citations

Economic Evaluation of Oral Alendronate Therapy for Osteoporosis in Chinese Postmenopausal Women: The Impact of Medication Compliance and Persistence

You

Liu

2020

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

Objective: Prevalence of osteoporosis in Chinese postmenopausal women has significantly increased over the past decade and oral bisphosphonates are the most potent antiresorptive drugs. The purpose of the present research was to evaluate the cost-effectiveness of oral alendronate for individuals with osteoporosis. We also assessed the impact of medication compliance and persistence on economic outcomes of alendronate and potential economic evaluations of persistence-enhancing interventions.Methods: We constructed an individual-level state-transition model to project health outcomes and costs of oral alendronate for Chinese postmenopausal osteoporotic women. The impact of medication compliance and persistence on economic evaluation was addressed in various scenario analyses. Model inputs were derived from clinical trials and published sources, where available. Deterministic and probabilistic sensitivity analyses were conducted to explore the impact of uncertainties and assumptions on the cost-effectiveness results.Results: Compared with no treatment, alendronate treatment was associated with an additional 0.052 QALYs (quality-adjusted life-years) at an additional cost of USD 738, which yielded an incremental cost-effectiveness ratio (ICER) of USD 14,192.308/QALY. The ICER for the different scenarios (full compliance, full persistence, and both full persistence and full compliance) was USD 4,933.333/QALY, USD 3,006.849/QALY, and USD 2,049.822/QALY, respectively. One-way sensitivity analysis showed the ICER was most sensitive to variations in time horizon and residual effect. Probabilistic sensitivity analysis demonstrated that, at a willingness to pay of USD 29,340/QALY, the probability that oral alendronate therapy will be cost-effective is approximately 80%.Conclusion: The findings support the view that oral alendronate is cost-effective for the treatment of osteoporotic fractures in Chinese postmenopausal women. Medication persistence is found to have a greater impact on cost-effectiveness than compliance and interventions to improve persistence to be an efficient use of resources.

show abstract

Antiosteoporosis effect of geraniin on ovariectomy‐induced osteoporosis in experimental rats

Wang

Cui

et al. 2021

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Osteoporosis is a skeletal condition that is characterized by decreasing bone density and deteriorating bone mass. The plant-based phytoconstituent such as geraniin possesses better therapeutic potentials in biomedical field. In the current experimental study, we planned to scrutinize the therapeutic potential of geraniin against ovariectomy (OVX)-induced osteoporosis in rats and find the possible mechanism.Healthy Sprague Dawley rats were randomized into six groups and subjected to geraniin and alendronate (ALN) treatment for 10 weeks. Body weight, uterus, femur weight, bone biochemical, bone turnover markers, inflammatory cytokine, calcium, phosphorus, vitamin D (Vit D), urine, hormones, and antioxidant level were estimated. Geraniin significantly (p < .001) reduced the level of bone turnover markers including beta-CrossLaps (β-CTx), ALN, osteocalcin (OC), alkaline phosphatase (ALP), and bone Gla protein (BGP); reduced the biomechanical parameters including maximum load, energy, stiffness, maximum stress, and Young's modulus; reduced the level of calcium (Ca) and phosphorus (P); and increased the level of vitamin D (Vit D) as compared with OVX-induced osteoporosis rats. Geraniin increased the level of bone structure parameters, namely bone mineral density, bone mineral content, tissue mineral density, bone volume fraction, and trabecular number; increased the level of osteoprotegerin (OPG) and OPG/RANKL; and reduced the level of receptor activator of nuclear factor kappa-Β ligand (RANKL). Geraniin significantly (p < .001) increased the level of glutathione (GSH) and reduced the level of malonaldehyde (MDA) in the liver, intestine, and bone of OVX-induced osteoporosis rats. Geraniin significantly (p < .001) decreased the level of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) pro-inflammatory cytokines.We also argue that geraniin could be an excellent candidate to treat and control bone-related disease or disorders.

show abstract

Cost-Effectiveness of Zoledronic Acid Versus Oral Alendronate for Postmenopausal Osteoporotic Women in China

Cited by 14 publications

References 43 publications

Osteoporosis: A Long-Term and Late-Effect of Breast Cancer Treatments

Osteoporosis: A Long-Term and Late-Effect of Breast Cancer Treatments

Economic Evaluation of Oral Alendronate Therapy for Osteoporosis in Chinese Postmenopausal Women: The Impact of Medication Compliance and Persistence

Antiosteoporosis effect of geraniin on ovariectomy‐induced osteoporosis in experimental rats

Contact Info

Product

Resources

About